Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 37
- Registration Number
- NCT05008666
- Locations
- 🇨🇳
Department of Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 20
- Registration Number
- NCT05004974
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Zhejiang University, Yiwu, Zhejiang, China
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05002686
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04994210
- Locations
- 🇨🇳
SunYat-sen university cancer center, Guangzhou, China
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-08-31
- Target Recruit Count
- 210
- Registration Number
- NCT04982939
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04973293
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT04967625
Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2022-11-08
- Target Recruit Count
- 48
- Registration Number
- NCT04961515
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04958473
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 29
- Registration Number
- NCT04954794
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.